News & Updates
Filter by Specialty:
IL-6 receptor antagonists benefit COVID-19 patients with high baseline death risk
Interleukin (IL-6) receptor antagonists provide significant clinical benefit in coronavirus disease 2019 (COVID-19) patients with high baseline mortality risk, a recent study has found. In contrast, such agents pose considerable threat when baseline mortality risk is low.
IL-6 receptor antagonists benefit COVID-19 patients with high baseline death risk
11 Nov 2021
Belimumab after rituximab reduces risk for severe flare in SLE
Treatment with belimumab following rituximab significantly lowers serum IgG anti-dsDNA antibody levels and the risk for severe flare in patients with systemic lupus erythematosus (SLE) that is refractory to conventional therapy, reveals a study.
Belimumab after rituximab reduces risk for severe flare in SLE
10 Nov 2021
Using wearables signals intent to improve health among individuals with mental illness
Among individuals living with depression and anxiety, the use of electronic wearable devices (EWDs) might be an indicator of their intent to lose weight and in turn may be valuable as a starting point for clinical interactions aimed at improving physical health, according to a recent study.